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ABSTRACT 
Background: The pancreas is an uncommon but recognizable site for metastases from renal cell carcinoma (RCC). 
Isolated pancreatic RCC metastases are still rarer and often present years after initial nephrectomy. Surgical resection 
has been the treatment of choice because of superior patient survival compared with traditional immunotherapy. In re- 
cent years, the advent of targeted therapy has transformed the outcomes of patients with metastatic RCC although little 
evidence is available on its effectiveness on this subset of patients. We report our experience of 6 patients with pan- 
creatic RCC metastases. Patients and Methods: Between 2007 and 2012, 6 patients (2 men, 4 women; median age 78 
years) were diagnosed to have pancreatic RCC metastases at our institute. The clinical features, treatment and outcomes 
were examined. Results: All 6 patients had a primary RCC of clear cell type. The median interval between initial cura- 
tive nephrectomy and re-presentation with pancreatic metastases was 12.5 years. Four patients were asymptomatic at 
the time of diagnosis, one presented with obstructive jaundice and another with acute gastrointestinal bleed. Four pa- 
tients had extra-pancreatic disease. All were deemed unsuitable or unfit for surgical metastasectomy. Five patients had a 
Memorial Sloan-Kettering Cancer Center (MSKCC) score of 1 (moderate risk) and the other patient had a score of 0 
(good risk). Two patients were commenced on Sunitinib, one received Pazopanib and one received Temsirolimus. Two 
patients did not undergo further treatment. Of the 4 patients who underwent targeted therapy, the median follow up was 
33 months with a median progression free survival of 16 months. One achieved complete response but recurred soon 
after treatment was stopped. Targetted therapy was recommenced and the disease remained stable. A second patient had 
long period of stable disease before disease progression. A third achieved partial response since started on targeted 
therapy and a fourth had disease progression despite treatment. Of the four patients who underwent systemic therapy, 
three are still alive at the time of this report. Conclusion: Pancreatic metastasis from RCC is a unique subgroup of dis- 
ease which runs an indolent course, and a higher incidence in an elderly population. Our results demonstrate that tar- 
geted therapy can be efficacious in some patients where surgical resection is not suitable or possible. 
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1. Introduction 
Pancreatic metastases are rare and renal cell carcinoma 
(RCC) is one of the few known tumours that metastasize 
to this site [1]. They can either present as part of dis- 
seminated disease or as isolated metastases. Historically, 
disease response and survival rates in patients on immu- 
notherapy-type systemic therapy have been disappointing 
[2-8], and surgical metastasectomy has been advocated in  
patients with resectable disease as they have shown su- 
perior outcomes [9-12].  
The introduction of targeted therapy has transformed 
the outcomes of patients with metastatic RCC (mRCC). 
Several clinical trials have shown that multi-targeted 
receptor tyrosine kinase (RTK) inhibitor such as sunitinib, 
pazopanib or monoclonal antibody avastin based bio- 
therapies have improved both the progression free (PFS) 
and overall (OS) survival of these patients. For example, 
Motzer’s multi-centre randomized phase III trial has shown 
that sunitinib doubled the median progression free sur- 
vival (PFS) when compared with immunotherapy such as 
interferon [13,14]. Similarly, Sternberg and colleagues 
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have found that pazopanib doubled the median PFS when 
compared with placebo but even more impressively, in 
treatment naïve patients, the median PFS quadrupled [15]. 
More recently, the COMPARZ trial has shown that both 
pazopanib and sunitinib are equally effective [16]. These 
agents have now become the current standard of care for 
first line treatment of mRCC [17,18].  
Pancreatic metastases from RCC tend to be princi- 
pally metachronous events. Although these patients may 
suffer from particular complications (such as biliary tree 
obstruction) due to its complex relation with its sur- 
rounding structures, current literature seems to suggest 
that they tend to have good prognostic indices and have a 
“slow-burning” course [19]. Real world data seem to 
suggest that RTK inhibitors can benefit patients across 
the spectrum of performance status and age although lit- 
tle is known about particular cohorts of patients with rare 
metastatic sites like the pancreas [20].  
2. Materials and Methods 
Between 2007 and 2012, 6 patients (2 men, 4 women; 
median age 78 years; range 59 - 80 years) were treated 
by the Department of Oncology in Hull and East York- 
shire NHS Trust. Primary tumour histology, interval be- 
tween primary treatment and re-presentation, presenting 
complaints and symptoms, diagnostic imaging and clini- 
cal outcomes including response rate and treatment toxi- 
city were evaluated. Statistical analysis was performed 
with Graphpad Prism 5 statistical software package (Gra- 
phPad. Software, La Jolla, CA).  
3. Results 
The demographics and clinical features of the 6 patients 
are summarized in Table 1. The median interval between 
initial presentation of primary tumour and diagnosis of 
pancreatic metastases was 12.5 years (range: 2 - 22 
years). Four patients were asymptomatic at the time of 
presentation; three were discovered during routine fol- 
low-up CT scans and one was an incidental finding on a 
CT for suspected lung carcinoma. Two patients were 
symptomatic at presentation, one with obstructive jaundi- 
ce and the other acute upper gastrointestinal haemorrhage. 
Histological sample was obtained in all 6 patients with 5 
underwent endoscopic ultrasonography fine needle aspir- 
ation and one percutaneous ultrasound guided pancreatic 
biopsy. All 6 patients had clear cell renal cell carcinoma 
in their initial tumours and pancreatic metastases (Figure 
1).  
The patient who presented with obstructive jaundice 
had multiple metastases in the pancreas but no extra- 
pancreatic disease. He underwent percutaneous cholan- 
giography and metallic biliary stent insertion to relieve 
his jaundice and was commenced on pazopanib (Figure 
2). The other patient who presented with acute upper 
gastrointestinal haemorrhage also had diffuse pancreatic 
metastases and also single renal metastases in her con- 
tralateral kidney. She underwent tumour embolization to 
control the bleeding and was treated with sunitinib (Fig- 
ure 3).  
Of the four asymptomatic patients, one had diffuse 
pancreatic metastases and a single liver metastasis. Due 
to his extensive cardiac history, he was commenced on  
 
  
(a)                           (b) 
Figure 1. (a) Histology from endoscopic ultrasound biopsy 
demonstrating classical appearance of clear cell RCC meta- 
stasis. (b) High expression of membranous claudin-1 pro- 
tein in clear cell RCC. 
 
 
Figure 2. Patient presented with obstructive jaundice. Cor- 
onal CT image demonstrated intrahepatic duct dilatation 
(black arrow) secondary to metastasis at the head of pan- 
creas (white arrow). Biopsy from endoscopic ultrasound 
confirmed clear cell RCC metastasis. 
 
 
Figure 3. Patient presented with acute upper GI haemor- 
rhage. Axial CT image showed the lesion has eroded 
through into the duodenum (white arrow). Active contrast 
extravasion indicating active haemorrhage (black arrow) 
was seen in the second and third part of the duodenum. The 
patient underwent tumour embolization for haemostasis. 
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Temsirolimus. Another patient also had multiple pancre- 
atic metastases but no extra-pancreatic disease. She was 
commenced on sunitinib. One of the remaining two pa- 
tients had a solitary pancreatic metastasis but also a syn- 
chronous metastasis in the contralateral kidney. This pa- 
tient was not suitable for systemic therapy due to her 
neurological comorbidities (several episodes of strokes) 
but underwent two radiofrequency ablation of the renal 
metastasis in her contralateral kidney. The other patient 
that did not receive any systemic therapy had multiple 
pancreatic metastases and also a liver metastasis. She 
was anephric due to nephrectomies for RCC on previous 
occasions and was on permanent haemodialysis.  
The median follow-up of the cohort was 33 months 
(range 11 - 72 months) after diagnosis of pancreatic RCC 
metastases. Of the four patients who received systemic 
therapy, the median follow up was 26 months (range 11 - 
72 months). They underwent regular CT scans to assess 
treatment response. Of the two patients who did not re- 
ceive any systemic therapy, one continued to have regu- 
lar follow-up CT scans for assessment of response from 
RFA. One patient had no further imaging and was only 
followed-up clinically and treated palliatively. The pa- 
tient who was given pazopanib had partial response with 
a PFS of 9 months. The patient developed stent related 
biliary sepsis 20 months after initial diagnosis and died 
from biliary sepsis. The patient who received temsi- 
rolimus had a PFS of 21 months before disease progres- 
sion but is alive at the time of this report (33 months fol- 
low-up). Of the two patients who received sunitinib, one 
achieved complete response after 24 months and sunit- 
inib was stopped. Twelve months after sunitinib was 
stopped, the patient had recurrence and she was restarted 
on sunitinib, achieving a partial response and her disease 
remained stable. The other patient who received sunitinib 
had stable disease and remained so on follow up after 11 
months (Figure 4).  
Overall, the median PFS for patients on systemic ther- 
apy was 16 months (range: 9 - 26 months) and the me- 
dian overall survival (OS) was 33 months (range 11 - 72 
months). Only one patient who was on systemic therapy 
died in our series as described above. The two patients 
who did not receive any systemic treatment passed away 
31 and 34 months after initial diagnosis respectively.  
4. Discussion 
Renal cell carcinoma (RCC) is relatively uncommon, 
representing 2% of all adult malignancies [21]. Due to 
the lack of any early warning signs, they often present 
late with advanced local or metastatic disease. At diag- 
nosis, around 20% - 30% of patients have synchronous 
metastases with a further 40% initially having localized 
disease will develop metachronous disease [1,22,23]. The 
pancreas is an unusual site for metastases, accounting for  
   
Figure 4. Partial response to sunitinib. On the selected pre- 
treatment axial CT image, a large pancreatic metastasis 
(white arrow) and a contralateral metastasis in the right 
kidney (white arrow) were seen. Six months after com-
mencing on sunitinib, both lesions have decreased in size. 
 
only 2% - 4% of all pancreatic lesions with colon, lung, 
breast, malignant melanoma along with RCC being the 
most common primary tumours [10,24,25]. 
Although pancreatic metastases are often considered 
as end stage events, there is a small but distinct group of 
patients that present with isolated pancreatic RCC meta- 
stases. The majority of them are from clear cell type 
[26-28], and they often present years after initial treat- 
ment [9,10,12].  
The mechanism with which metastatic RCC spreads to 
the pancreas is poorly understood. Sellner and colleagues 
have analyzed a large cohort of pancreatic metastases 
from RCC and have concluded that haematological 
spread is the most likely mechanism due to diffuse dis- 
tribution of pancreatic metastases irrespective of the site 
of RCC and absence of concurrent metastases to other 
organs [9].  
Surgical resection has been advocated by many studies 
as the treatment of choice [2-4,9,10,12]. Many case se- 
ries have demonstrated that resection of metastases in 
other organs such as liver, lung and brain have improved 
survival and quality of life [29,30]. In a recent systematic 
review, Tanis have shown that this is also the case in 
pancreas. They reviewed 311 patients who underwent 
pancreatic metastasectomy for mRCC and compared 
them with 73 patients who were managed medically and 
have shown that the overall 2 and 5 year survival were 
significantly higher for the surgical group (80.6% and 
72.6% compared to 41% and 14% respectively) [12].  
The main reasons cited for non-operative management 
were local irresectability, poor performance status and 
the presence of extra-pancreatic disease [12]. However, 
most patients presented with isolated pancreatic metasta- 
ses usually possess one or more of these factors. The me- 
dian age for pancreatic metastases from RCC occurs in 
the 7th decade of life and between 20% - 45% of these 
metastases are multifocal [31]. Our cohort reflects the 
“real-life” situation where the patients are elderly, and 
not suitable for surgical intervention due to other co- 
morbidities. The median age at presentation in our cohort 
was 78 years. In 5 out of our 6 patients, there were dif- 
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fuse pancreatic metastases. Three patients had multiple 
comorbidities precluding them from surgery (one had 
cardiac disease, one was anephric on haemodialysis after 
both kidneys were removed due to RCC and another had 
debilitating neurological co-morbidities as a result of 
previous episodes of strokes). Four patients had extra- 
pancreatic disease involving the liver, contralateral kid- 
ney and lung metastases.  
For patients who were not suitable for surgery, they 
were traditionally treated by immunotherapy such as in- 
terleukin-2 or IFNa since RCC is not responsive to tradi- 
tional chemotherapy. However, the response rate with 
these agents were often poor (as low as 5% - 20%) with 
the median survival of these patients of usually 12 mon- 
ths and a 5 year survival rate of around 10% [3,5-8]. In 
recent years, the emergence of targeted therapy has trans- 
formed the management and outcomes of patients with 
mRCC [14,15,32-34]. The three systemic therapies that 
were used in our patients have all shown encouraging 
results. In a randomized phase III trial with 750 patients, 
Motzer and colleagues had showed the median PFS in 
patients receiving sunitinib, an oral multi-targeted recap- 
tor tyrosine kinase (RTK) inhibitor, have more than dou- 
bled that of IFNa (11 vs 5 months). The OS had also in- 
creased by nearly 5 months (26.4 vs 21.8 months) [14]. 
Similarly, Sternberg and colleagues had demonstrated 
that pazopanib, another RTK inhibitor, had significantly 
prolonged the median PFS compared with placebo in 
treatment naïve patients (9.2 months vs 2.8 months) and 
achieved a tenfold increase in response rate (30% vs. 3%) 
[15]. As for temsirolimus, a mTOR inhibitor, it was 
shown to double the median PFS (3.8 vs 1.9 months) 
months and increased median OS (10.9 vs 7.3 months) 
when compared to IFNa in a phase III trial [32].  
Some of the drawbacks in this study are the small 
number of patients and the heterogeneous treatment they 
received with different targeted therapies used. However, 
isolated pancreatic RCC metastases are rare and although 
our cohort is small, our results suggest a significant sur-
vival benefit when compared to survival of 41% at 2 
years and 14% at 5 years for the non-surgically treated 
group in Tanis’ systematic review [12], particularly if 
one factors in the median age and “real world” characte- 
ristics of our cohort. With a median PFS of 15 months 
and median OS of 31 months our data is generally com- 
parable to results from other clinical trials [13-15]. Of the 
4 patients who underwent systemic therapy, 3 are still 
alive at the time of this study with a median follow-up of 
26 months (range 9 - 70 months). The two patients who 
did not receive any further treatment had survived 31 and 
34 months after diagnosis underscoring the recognized 
indolence of the metastatic disease in this group, running 
a much less aggressive course and having particularly 
long median overall survival [31].  
5. Conclusion 
Our results in this rare group of patients demonstrate that 
targeted treatments can be used safely in elderly patients 
who are usually unfit for surgery or their disease is un- 
suitable for pancreatic resection and can improve out- 
comes even in these better prognosis metastatic patients. 
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